ERCC1 and lung adenocarcinoma: In a recent study carried out by Li and co-workers, it was reported that ERCC1 overexpression inhibited the activation of the EGFR and stimulated resistance in lung adenocarcinoma cells to the combined therapy of cetuximab and cisplatin [74].